Swedish Biotech Oasmia Settles Investor Claims For $2.4M
A New York federal judge on Wednesday gave preliminary approval to a $2.4 million settlement to end claims from investors that Swedish biotechnology company Oasmia Pharmaceutical AB hid deals it had...To view the full article, register now.
Already a subscriber? Click here to view full article